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Abstract
Neuropilin-1 (NRP1) is a transmembrane protein acting as a co-receptor for several growth
factors and interacting with other proteins such as integrins and plexins/semaphorins. It is
involved in axonal development, angiogenesis and cancer progression. Its primary mRNA
is subjected to alternative splicing mechanisms generating different isoforms, some of
which lack the transmembrane domain and display antagonist properties to NRP1 full size
(FS). NRP1 is further post-translationally modified by the addition of glycosaminoglycans
(GAG) side chains through an O-glycosylation site at serine612. Here, we characterized a
novel splice variant which has never been investigated, NRP1-Δ7, differing from the NRP1-
FS by a deletion of 7 amino acids occurring two residues downstream of the O-glycosyla-
tion site. This short sequence contains two aspartic residues critical for efficient glycosyla-
tion. As expected, the high molecular weight products appearing as a smear in SDS-PAGE
and reflecting the presence of GAG in NRP1-FS were undetectable in the NRP1-Δ7 pro-
tein. NRP1-Δ7 mRNA was found expressed at an appreciable level, between 10 and 30%
of the total NRP1, by various cells lines and tissues from human and murine origin. To
investigate the biological properties of this isoform, we generated prostatic (PC3) and
breast (MDA-MB-231) cancer cells able to express recombinant NRP1-FS or NRP1-Δ7 in a
doxycycline-inducible manner. Cells with increased expression of NRP1-Δ7 were charac-
terized in vitro by a significant reduction of proliferation, migration and anchorage-indepen-
dent growth, while NRP1-FS had the expected opposite “pro-tumoral” effects. Upon VEGF-
A165 treatment, a lower internalization rate was observed for NRP1-Δ7 than for NRP1-FS.
Finally, we showed that NRP1-Δ7 inhibited growth of prostatic tumors and their vasculariza-
tion in vivo. This report identifies NRP1-Δ7 as a splice variant displaying anti-tumorigenic
properties in vitro and in vivo, emphasizing the need to consider this isoform in future
studies.
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Introduction
The neuropilin-1 (NRP1) gene is located on chromosome 10p12 and composed of 17 exons
[1]. It encodes a transmembrane protein involved in axonal development, angiogenesis and
cancer progression [2]. It acts as a co-receptor for several growth factors including some vari-
ants of VEGF, EGF, HGF, FGF, TGF-β and PDGF [3–7], and it also interacts with other trans-
membrane proteins such as integrins and plexins/semaphorins [8, 9].
NRP1 can be considered as a proteoglycan since it can bemodifiedby the addition of glycos-
aminoglycan side chains [10–12]. Serine612 has been identified as the site of O-glycosylationwhere
long chains of oligosaccharides assemble on the protein. The nature of the chains attached on
NRP1 depends on the cell type. In smoothmuscle cells, NRP1 is predominantly glycosylatedwith
chondroitin sulfate while it is derivatizedwith heparan sulfate in endothelial cells [12]. The number
and the nature of the glycosaminoglycans linked to a protein strongly modulate its function.This
has also been observed for NRP1.Mutation of Ser612 into Ala prevents O-linked glycosylation and
markedly affects the biological functions of NRP1 [10, 13]. The suppression of the glycosaminogly-
can side chains by enzymatic digestion similarly results in altered NRP1-driven cell invasion [10].
The full size NRP1 (NRP1-FS, 923 aa) is known as a pro-angiogenic and pro-tumorigenic
factor [13, 14]. Alternative splicing mechanisms occurringon its primary transcript generate
different protein isoforms with sizes varying from 551 to 907 amino acids [1] (Fig 1). Four vari-
ants (NRP1-s11, s12, sIII and sIV) lacking the transmembrane domain are soluble and able to
bind VEGF-A165 but exert anti-angiogenic and anti-tumorigenic effects by sequestration of
NRP1 binding growth factors and competition with their signaling pathways [15, 16]. NRP1-
ΔE16, resulting from the skipping of exon 16 and its replacement by the “AAG” Arg triplet,
does not display any functional difference as compared to the NRP1-FS [17].
In the present work, we have identified and studied a so far uncharacterized splice variant of
NRP1. Although this variant is quite abundant (10 to 30% of the total amount of NRP1), it was
never specifically reported before, most probably because it differs from the NRP1-FS variant
by the absence of only 7 amino acids, which prevents its identification on SDS-PAGE. This
deletion is located two residues downstream of the O-glycosylation site on serine612 and con-
tains two aspartic residues that are critical for efficient glycosylation [18]. We have therefore
determined if the modification of the consensus sequence around Ser612 affected the glycosyla-
tion status and the functions of this new NRP1 variant.
Materials and Methods
Reagents and Cells
Doxycyline hyclate (D9891) was from Sigma-Aldrich (USA). Rabbit monoclonal anti-neuropi-
lin-1 (ab81321) was from Abcam (UK). Rabbit polyclonal anti–extracellular signal-regulated
kinase (ERK1/2) (M-5670) and mouse monoclonal anti-FLAG (F1804) were from Sigma-
Aldrich. Rabbit polyclonal anti-Tet-repressor antibody (TET01) was fromMoBiTec (Ger-
many). The secondary horseradish peroxidase–conjugated rabbit anti-mouse IgG (P0260) and
swine anti–rabbit IgG (P0217) were from DAKO (Belgium). PC3 human prostate adenocarci-
noma cells were cultured in F-12 Kaighn's medium (Invitrogen, Belgium) supplemented with
7% fetal bovine serum (FBS) (Lonza, Belgium).MDA-MB-231 human breast adenocarcinoma
cells were cultured in DMEM (Lonza) supplemented with 10% fetal bovine serum.Human
skin fibroblasts, HSMC (human smoothmuscle cells), HUVEC (human umbilical vein endo-
thelial cells), HT1080 (human fibrosarcoma cells) and MCF7 (human breast adenocarcinoma
cells) were cultured in DMEM supplemented with 10% FBS, MO59J (human malignant glio-
blastoma cells) were cultured in DMEM/F12 (Lonza) supplemented with 10% FBS and
Neuropilin-1-Δ7 Is Anti-Tumorigenic
PLOS ONE | DOI:10.1371/journal.pone.0165153 October 31, 2016 2 / 21
from Research Concerted Actions of the University
of Liège (ARC, #10/15-02 (YD); https://www.ulg.
ac.be/cms/c_337341/fr/actions-de-recherche-
concertees-arc). AC is a Senior Research Associate
and CD a Research Associate, both at the Belgian
F.R.S.-FNRS. The funders had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
OCI-LY-19 (human lymphoma cells) were cultured in RPMI 1640 (Lonza) supplemented with
10% FBS. Murine 4T1, LLC, NIH3T3 and B16F10 were cultured in DMEM supplemented with
10% FBS. RNA from human normal breast, placenta and skin were obtained from the Surgery,
Obstetrics and GynecologyDepartment and from the DermatologyDepartment.Mouse RNA
was purified from 8-weeks old C57Bl6 mice.
Western Blotting
Cells were lysed in Laemmli buffer and proteins were separated by polyacrylamidegel electro-
phoresis. Proteins were transferred to a PVDF Transfer Membrane (NEN Life Science Products,
Fig 1. (A) Schematic representation of the main known and putative neuropilin-1 splice variants. The exons of the neuropilin-1
isoforms are depicted by grey boxes while the black boxes correspond to intronic sequences retained into some splice variants.
Deletions are represented by a black line. The boxes are not scaled to the size of the exon. The position of the primers used to co-
amplify the NRP1 variants are indicated with black arrows. (B) Schematic representation of the protein domains of NRP1-FS and
NRP1-Δ7. The deleted 7 amino acids sequence in NRP1-Δ7 in the vicinity of Ser612 is shown between brackets.
doi:10.1371/journal.pone.0165153.g001
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USA) which was then blocked for 1 hour with 3% drymilk in PBS-0.05%Tween 20 and incubated
for 4h with the primary antibody. After 3 washings, membranes were incubatedwith the secondary
horseradish peroxydase-conjugated antibody for 1h, and revealed by chemoluminescenceusing
home-made ECL acquired with the ImageQuant LAS4000 device (GEHealthcare, USA). The
membranes were re-probedwith anti-ERK1/2 antibodies used as a control for protein loading.
RT-PCR
Total RNA was purified from cells with the High Pure RNA Isolation Kit (Roche, Switzerland)
and from tissues with Ambion kit using TRIzol reagent (ThermoFisher, USA), following the
instructions of the manufacturer. Reverse Transcription-Polymerase Chain Reactionwas per-
formed using Tth DNA Polymerase kit (Roche). The primers 5’-GCTGTGAAGTGGAAGCC
CCTACA-3’ (forward) and 5’-GGTCTTGTGAGAGCCCCAGCCA-3’ (reverse) were used to
amplify NRP1-FS and NRP1-Δ7 in human samples. The primers 5’-GTGGATGAGTGTGAC
GACGACCA-3’ (forward) and 5’-GAGAGCCCCAGCCAAACTCGCA-3’ (reverse) were used
to amplify NRP1-FS and NRP1-Δ7 in murine samples. The amplification products of the two
isoforms were separated on a polyacrylamide gel and quantified. Primers 5’-CTTGGTGGG
ATTGCTGTGGATGAC-3’ (forward) and 5’-GGGCACTCATGGCTATGATGGTGA-3’
(reverse) were used to amplify NRP1-ΔE16. Primers 5’-GGTGGATGAATGTGATGACGA
CCA-3’ (forward) and 5’-GTCACATTTCGTATTTTATTTGATACCTGA-3’ (reverse) were
used to amplify NRP1-s12. Primers 50-GTTCACCCACTAATAGGGAACGTGA-3 0 (forward)
and 50-GATTCTGACTTAGAGGCGTTCAGT-30 (reverse) were used to amplify human and
mouse 28S rRNA. Primers 5’-TCCAGCTCTCTCCACGCGATTCA-3’ (forward) and 5’-ATG
ACCGTGGGCTTTTCTGTGGC-3’ (reverse), specific of human NRP1, were used in the in
vivo experiments.
RT-qPCR
RT-qPCR was performed as previously described [19]. One μg of total RNA was reversed tran-
scribed using SuperScript III Reverse Transcriptase (Invitrogen). Primers 5’-GCTGTGAAGT
GGAAGCCCCTACA-3’ (forward) and 5’-TGCCACCTGTGAGCTGGAAGTCA-3’ (reverse)
were used to specifically amplify NRP1-FS in human cells and tissues. Primers 5’-GCTGTAA
GTGGAAGCCCCTACA-3’ (forward) and 5’-TGGTGCCACCTGTTCCACTGTG-3’ (reverse)
are specific for human NRP1-Δ7. In mice, 5’-GGCTGTGAAGTGGAAGCACCTAC-3’ (for-
ward) and 5’-TGCCTCCTGTGAGCTGGAAGTCA-3’ (reverse) amplified NRP1-FS whereas
5’-GGCTGTGAAGTGGAAGCACCTAC-3’ (forward) and 5’-TGGTGCCTCCTGTGCCAC
TGTG-3’ (reverse) amplified NRP1-Δ7. Primers specific for human and mouse GAPDH were
describedpreviously [20]. Real-time qPCR was performed in a final volume of 20 μl containing
2 μl cDNA (corresponding to 10 ng of total RNA), 300 nM of each primer and 10 μl qPCR
MasterMix Plus for SYBR green assays (Eurogentec, Belgium) in the StepOne Real-Time PCR
system (Applied Biosystems, Belgium). The polymerase was activated at 95°C for 3 min and
the PCR conditions for amplification were 15 sec at 95°C, 20 sec at 66°C and 20 sec at 72°C.
The results were analyzed with the StepOne Software. qPCR amplifications were performed in
triplicate. The amplification efficiencies of both variants were close to 100% and not signifi-
cantly different. The relative expression of the two variants was calculated using the formula
2(-ΔΔCt). The specificity of the amplification products was assessed by gel electrophoresis.
Deep Sequencing
MCF7 were isolated and prepared for next-generation sequencing analysis, as described in a
previous publication [20]. The average number of reads approached or exceeded 20 millions.
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Alignment of transcripts to the genome indicated that 16733 genes were expressed in the sam-
ple. Detailed protocol and sequencing data are available in the ArrayExpress database (www.
ebi.ac.uk/arrayexpress) under accession number E-MTAB-5104.
Generation of PC3 and MDA-MB-231 Cells Expressing NRP1-FS,
NRP1-Δ7, FLAG-NRP1-FS and FLAG-NRP1-Δ7 in a Doxycycline-
Dependent Way
MDA-MB-231 cells were transfected with pcDNA6/TR (Invitrogen) and selected in medium
supplemented with blasticidin (4 μg/ml). One clone expressing a high level of tetracycline
repressor (MDA-MB-231/TR) was isolated. PC3 cells expressing a high level of tetracycline
repressor (PC3/TR) were describedpreviously [19]. The entire sequences of NRP1-FS and
NRP1-Δ7 were amplified by RT-PCR, cloned into pcDNA4/TO (Invitrogen), and sequenced.
FLAG-taggedNRP1-FS and NRP1-Δ7 were generated by PCR-based approach by introducing
(between the codon encoding Lys26 and the codon encodingCys27) the FLAG sequence
(AspTyrLysAspAspAspAspL ys) by using the primers 5’-GACTACAAGGATGACGATGAC
AAGTGTGGCGATACTATA AAAATTGAAAGC-3’ and 5’-CTTGTCATCGTCATCCTTG
TAGTCTTTATCGTTGCGAAAAGCGCCGGC-3’. PC3/TR and MDA-MB-231/TR were
transfected with pcDNA4/TO/NRP1-FS, pcDNA4/TO/NRP1-Δ7 or pcDNA4/TO/FLAG-
NRP1-FS, pcDNA4/TO/FLAG-NRP1-Δ7 and selected in medium supplemented with blastici-
din (1 μg/ml) + Zeocin (200 μg/ml) for PC3 cells and blasticidin (2 μg/ml) + Zeocin (400 μg/ml)
for MDA-MB-231 cells. Several clones expressing in a doxycycline-dependentway NRP1-FS,
NRP1-Δ7, FLAG-NRP1-FS or FLAG-NRP1-Δ7 were isolated and used in this study.
Immunoprecipitation
Cells were chilled on ice and lysed in buffer containing 1% Igepal, 150 mMNaCl, 20 mM Tris/
HCl pH 7.4, 0.1mMAEBSF and 4 μg/ml aprotinin. Lysates were centrifuged for 10 min at
16000g at 4°C. Supernatants were incubated with 1 μg/ml rabbit anti-NRP1 or anti-FLAG anti-
bodies. After 2h of incubation at 4°C, 30 μl of protein A–Sepharose beads (GE Healthcare, UK)
were added for 1h to capture immune complexes. Beads were washed four times in ice-cold
lysis buffer and boiled in 60 μl of SDS–PAGE lysis buffer. The samples were subjected to west-
ern blotting as described above.
Scratch Assay
A suspension of 50 000 PC3 or 35 000MDA-MB-231, each inducible for NRP1-FS or -Δ7, was
seeded into culture-inserts (#80209, Ibidi, Germany) with or without 200 ng/ml doxycycline in the
medium. This type of insert allows the creation of a homogeneous 500 μmwidth cell-free space in
themiddle of a confluent cell monolayer. Twenty-four hours after seeding, the inserts were
removed and pictures by phase-contrast microscopy of the resulting scratches were taken at T0 (2
pictures/insert, 6 inserts/conditionand experiment for each tested clone was performed at least
twice). PC3 andMDA-MB-231 were cultured for a further 24h and 8h, respectively. Cellmigration
was evaluated by measuring the cell-free surface at the beginningof the experiment (T0) and the
surface covered by the cells at the end of the experiment by using ImageJ Software (National Insti-
tute of Health, USA). Results are expressed as the percentage of wound closure in each condition.
Proliferation Assay
Cells were seeded in 24 wells costar plates (7500 cells/well) and allowed to attach overnight
(PC3) or for 2h (MDA-MB-231). Half of the cultures were supplemented with doxycycline
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(day 0) and cells were collected after 1, 3 and 5 days (PC3) or after 1, 2 and 3 days (MDA-MB-
231). DNA content was assayed by a fluorimetric technique using bisbenzimide and a micro-
plate Gemini EM spectrofluorimeter (Molecular Devices,USA).
Cell Apoptosis
PC3/NRP1-FS and PC3/NRP1-Δ7 cells were cultured in absence and presence of doxycycline
and apoptosis was evaluated by FACS after annexin V–FITC and propidium iodide staining, as
previously described [19] using a FACSCanto II double LASER flow cytometer (UV, 488 nm,
633 nm) (BD Biosciences, Belgium).Data were analyzed using FACSDiva Software (BD
Biosciences).
Soft Agar Assay
Anchorage-independent growth was determined by soft agar assay [21]. A total of 2 × 103 PC3
cells or of 5 × 103 MDA-MB-231 cells overexpressing NRP1-FS or NRP1-Δ7 in a doxycycline-
dependent way were plated in 60-mm dishes in growth medium containing 0.3% agar, on top
of a 0.6% agar gel. The overexpression of the transgene was induced by addition of 1 μg/ml
doxycycline. After 21 days, colonies were counted in the whole dishes using an inverted phase-
contrast microscope. Results are expressed as the mean number ± SD of two independent
experiments performed in quadruplicate.
VEGF Treatment of PC3/FLAG-NRP1-FS and PC3/FLAG-NRP1-Δ7
Cells were serum starved and treated with doxycycline during 24h. Recombinant VEGF-A (iso-
form 165 at 37 ng/ml) [4] was added in some cultures for 10 minutes. After fixation with 4%
paraformaldehyde in PBS for 15 min and permeabilizationwith 0.25% Triton X-100 in PBS for
10 min, the samples were blocked with 10% bovine serum albumin in PBS for 30 min before
incubating for 2h with a monoclonal mouse anti-FLAG (1:500 in PBS). After three washings,
the samples were incubated for 1h with a goat anti-mouse Alexa Fluor 555-conjugated anti-
body (1:500 in PBS) and counterstained with DAPI (2.5 μg/ml). Fluorescent labeling was
assessed by using an epifluorescent Nikon TiS microscope. For each cell, a Z stack was per-
formed by using NIS Elements software. By using ImageJ software, the fluorescencewas mea-
sured in the whole cell (membrane-associated and intracellular vesicles) and in a zone free of
vesicles. The maximum pixels value in this vesicle-free zone was taken as the threshold beyond
which fluorescencewas considered to be associated with intracellular vesicles. The pixels values
above the threshold measured in the whole cell were summed and expressed in % of the total
fluorescence.
Tumor Xenograft
Experimental protocol was approved by the local ethical committee (University of Liège,
approval document n°1293). Nude mice (6 week-old, Charles River Laboratories, USA)
received an intraperitoneal injection of 60 mg/kg Nembutal before to be subcutaneously
injected in each flank with 2 x 106 PC3 conditionally expressing NRP1-Δ7. Control mice had
access to regular water while doxycycline (2 mg/ml) was added in drinkingwater of induced
mice. The general condition of mice was monitored daily by visual examination during the
entire experiment and tumor volume was evaluated ((length x width x thickness) x π/6, as
determined using a caliper). Signs of pain were never observed and the calculated tumor vol-
umes remained always largely below 1 cm3 which is considered as the upper acceptable limit
for subcutaneous tumors. After 7 weeks, mice were sacrificedby cervical dislocation followed
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by decapitation and the collected tumors were photographed, dissected,measured and
weighed. Fragments of tumors were then used for immunohistological analyses and RNA
extraction.
Immunohistological Analysis of Tumors
Antigen retrieval was performed on 5 μm sections of PC3 tumors by heating at 126°C for 11
minutes in Target RetrievalCitrate buffer (pH 6, Dako, Denmark). After blocking endogenous
peroxydases and non-specific antigenic sites (Universal Blocking Reagent, Biogenex, USA),
sections were incubated with primary anti-CD31 antibodies (diluted 1:150 in BSA/PBS 1%) for
1h, followed by biotinylated secondary antibodies (diluted 1:300) for 30 minutes and with
HRP-conjugated streptavidin (diluted 1:500) for 30 minutes. Signal was amplified by an incu-
bation in Biotinylated Tyramide (diluted 1:100, Perkin Elmer, USA) for 10 minutes, followed
by additional 30 minutes in HRP-conjugated streptavidin. Staining was performedwith AEC
+ High Sensitivity Chromogen (Dako, Denmark) followed by a counterstaining with hematox-
ylin. Stained sections were scanned with a NanoZoomer slide scanner (Hamamatsu Photonics,
Japan) and quantification was performed using ImageJ software (National Institute of Health,
USA). Tumor vascularizationwas quantified both as the number of blood vessels per unit sur-
face and as the % of surface covered by blood vessels.
Statistical Analyses
Statistical analyses were performed using UMann-Whiney test or by an Anova test (GraphPad
Prism software, GraphPad Sofware, La Jolla, CA, USA) with p 0.05 considered as significant.
Results
Characterization of a Novel Variant of NRP1: NRP1-Δ7
During an exploratory experiment aiming at determining the expression of the different splice
variants of NRP1, several primer pairs were designed and used, including primers at the
exon10/exon11 (forward) and exon12/exon13 (reverse) junctions (Fig 1). In addition of the
expected 233bp product, a smaller fragment was reproducibly and significantly co-amplified. It
was cloned and sequenced, showing that it results from the splicing of intron 11 at an alterna-
tive donor site (AG-gtgat) in exon 11 located 21 bases upstream of the usual splice site (AG-
gtgca). This deletion does not change the reading frame of the mRNA and is responsible, at the
protein level, for the absence of a 7 amino acids long sequence explaining the name given to
this variant (NRP1-Δ7). The actual existence of this variant of NRP1 was further confirmed by
different independent observations. Its presence was first evaluated in various cell lines and tis-
sues of human or mouse origin by regular RT-PCR followed by gel electrophoresis. The relative
proportion of NRP1-Δ7 was also determined by RT-qPCR using variant-specific primers. The
ratio Δ7/FS varies between 0.13 and 0.43 (Fig 2). As an additional approach, the existence and
presence of NRP1-Δ7 was also evaluated in “Deep Sequencing” data previously obtained using
MCF7 cells mRNA [20]. From such data, the abundance of alternative splicing variants can be
calculated by comparing their FPKM (Fragments Per KilobaseOf Exon Per Million Fragments
Mapped). Values of 29.13 and 12.18 were obtained for NRP1-FS and NRP1-Δ7, which corre-
spond to a ratio of 29%. Finally, the existence of NRP1-Δ7 is further assessed by its identifica-
tion by the German Genome Project (clone DKFZp686E15115; http://www.ncbi.nlm.nih.gov/
nuccore/BX648250.1) by entries in Genbank under the accession numbers NM_001244973
(NRP1 variant 5) and NP_001231902 (NRP1 isoform E). Based on the exon content of the pre-
viously described variants of NRP1, NRP1-s12 and NRP1-ΔE16 should be also affected by the
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21 bases deletion. It was confirmed for NRP1-s12 (NRP1-s12-Δ7), while it was not further
investigated for NRP1-ΔE16 which is barely detectable in our cell models (S1 Fig).
NRP1-Δ7 Displays Reduced O-Linked Glycosylation
Recombinant proteins were produced to identify potential functional consequences of the 7 aa
deletion. HEK293 cells were transiently transfected with an expression vector for NRP1-FS or
NRP1-Δ7, while PC3 cells were transfected with a vector expressing FLAG-taggedNRP1-FS or
NRP1-Δ7 to allow discriminating exogenous and endogenous NRP1. They were immune-pre-
cipitated, respectively, with anti-NRP1 and anti-FLAG antibodies and subjected to western
blot analysis revealed by anti-NRP1. As illustrated in Fig 3, a substantial fraction of NRP1-FS
migrated as highmolecular weight products forming a smear corresponding to proteoglycan-
modifiedNRP1 [10, 12]. Remarkably, these highmolecular weight products were far less abun-
dant in NRP1-Δ7 overexpressing cells, both in HEK and PC3 cells. These results suggest that
the 7 aa deletion close to Ser612 affects its glycosylation because it changes the consensus
sequence required for optimal O-glycosylation. These results also show that our cell models are
adequate for investigating the biological functions of NRP1-Δ7. To improve the significance of
the results of our biologicalmodels and avoid potential off-target effects linked to the use of
Fig 2. NRP1-Δ7 is expressed in various cell types and tissues. RT-PCR analysis was performed on total RNA extracted
from cells and tissues from human (A) and mouse (B) origin as detailed in Materials and Methods. The higher molecular
weight product of 233bp is amplified from NRP1-FS (FS) while the lower molecular weight product of 212bp is amplified from
NRP1-Δ7 (Δ7). 28S rRNA amplification was used as control for RT-PCR. Quantifications of NRP1-Δ7 and NRP1-FS were
also performed by RT-qPCR on the same RNA. The ΔCt for each isoform and their relative abundance are shown in S2 Fig.
Only the calculated ratios (Δ7/FS) are provided here.
doi:10.1371/journal.pone.0165153.g002
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different clones, we then generated inducible clones overexpressing NRP1-FS and NRP1-Δ7
upon treatment by doxycycline.
Generation of Inducible PC3 and MDA-MB-231 Clones Overexpressing
NRP1-FS or NRP1-Δ7
PC3 and MDA-MB-231 cancer cells are known to constitutively express a significant level of
NRP1 and to respond to NRP1-mediated signaling [22–24]. In order to benefit from a robust
experimentalmodel, we decided to create inducible clones expressing recombinant NRP1
(either FS or Δ7) only upon stimulation by doxycycline added in the culture medium. The
advantage of this model is that each clone can be used as its own control by comparing its phe-
notype in absence and presence of inducer, an experimental setting much more reliable and
biologically relevant than the comparison of different cell lines. We generated doxycycline-
inducible PC3 and MDA-MB-231 clones overexpressing NRP1-FS (PC3/TR/NRP1-FS and
MDA/TR/NRP1-FS) or NRP1-Δ7 (PC3/TR/NRP1-Δ7 and MDA/TR/NRP1-Δ7). Two clones
of each type for PC3 and one clone of each type for MDA-MB-231 were isolated and amplified
for further investigations. In control conditions without doxycycline the ratio Δ7/FS represents
roughly 0.17 to 0.33 (Fig 4 and S3 Fig). Upon stimulation of expression of recombinant NRP1
Fig 3. NRP1-Δ7 protein is less glycosylated than NRP1-FS protein. (A) HEK293 cells were mock-transfected (NT) or
transfected with an expression vector for NRP1-FS (FS) or NRP1-Δ7 (Δ7). (B) PC3 cells were transfected with an expression
vector for FLAG-NRP1-FS (FS) or for FLAG-NRP1-Δ7 (Δ7). Cells were lysed 48h after transfection and lysates were
subjected to immunoprecipitation with anti-NRP1 (A) or anti-FLAG (B) antibodies. The immune-precipitates were subjected
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Fig 4. Characterization of the doxycycline-inducible clones. PC3 or MDA-MB-231 (MDA) clones with inducible expression of
recombinant full size NRP1 (FS) (A) or recombinant NRP1-Δ7 (Δ7) (B) were cultured for 24h in absence (-) or presence (+) of
doxycycline (dox) at 200 ng/ml. For each clone, cells were processed for total RNA extraction to perform RT-PCR and RT-qPCR
Neuropilin-1-Δ7 Is Anti-Tumorigenic
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by doxycycline, this ratio drops to 0.10 in NRP1-FS clones and increases up to 0.60–0.90 in
NRP1-Δ7 clones, as measured by RT-qPCR. Western blotting analysis, which cannot discrimi-
nate the two isoforms, indicates a maximum of 2-fold increase in total NRP1 protein
expression.
NRP1-FS and NRP1-Δ7 Differentially Regulate Cellular Functions In
Vitro
It is known that NRP1 can affect various cellular functions, such as migration or proliferation,
which are relevant to cancer progression [25]. The migration of PC3 cells conditionally overex-
pressing NRP1-FS or NRP1-Δ7 was assessed in a scratch wound healing assay (Fig 5). As
expected, overexpression of NRP1-FS significantly enhanced the migration rate of PC3 cells
whereas it was significantly inhibited in cells overexpressing NRP1-Δ7. Similar results were
obtained with a second PC3 clone of each type (NRP1-FS or NRP1-Δ7) and confirmed in
MDA-MB-231 clones, showing that this regulation is not limited to a single cell type (S5 Fig).
The proliferation rate of PC3 and MDA-MB-231 cells was also increased upon overexpression
of NRP1-FS, while being reduced in cells overexpressing NRP1-Δ7 (Fig 6). These effects were
not related to alterations of apoptotic processes which were not influenced by the overexpres-
sion of either variant as shown by flow cytometry analyses (S6 Fig). The consequences of the
overexpression of NRP1-FS and NRP1-Δ7 on the in vitro tumorigenic properties of PC3 and
MDA-MB-231 cells were further evaluated in an anchorage-independent growth model. Cells
were seeded in soft agar in absence and presence of doxycycline and the total number of colo-
nies formed after 3 weeks was counted. The overexpression of NRP1-FS in both cell types sig-
nificantly increased the number of colonies while overexpression of NRP1-Δ7 had the opposite
effect (Fig 7). It has to be noticed that doxycycline by itself did not affect the phenotype of PC3/
TR cells transfected with an empty pcDNA4/TO or of MDA-MB-231/TR in the three experi-
mental models, confirming that the observed effects are specifically related to the transgene
overexpression (S4 Fig). Altogether, these data demonstrate an opposite effect of NRP1-FS and
NRP1-Δ7 on the in vitro tumorigenic properties of PC3 and MDA-MB-231 cells.
NRP1-FS and NRP1-Δ7 Are Differentially Relocalized upon VEGF-A165
Stimulation
NRP1 is a well-known co-receptor for VEGF. PC3 inducible clones expressing the FLAG-
taggedNRP1-FS or NRP1-Δ7 were cultured in presence of doxycycline and exposed to
VEGF-A165 for 10 min. Immunofluorescence labeling was performedwith an anti-FLAG anti-
body and the fluorescence associated with the membrane and intracellular vesicles was quanti-
fied on Z stacked sections as detailed in Materials and Methods. As illustrated in Fig 8,
VEGF-A165 treatment induced a significant relocalization of NRP1-FS in intracellular vesicles
with a concomitant reduction of membrane-associated fluorescence. No significant difference
in the compartmentalization of the NRP1-Δ7 was observed after VEGF-A165 treatment.
analyses or lysed for western blotting visualization using an anti-NRP1 antibody. PC3 and MDA-MB-231 cells express
endogenous NRP1-FS and NRP1-Δ7, which can be identified as two RT-PCR products in absence of dox. The ΔCt of each
isoform were measured by SYBR green RT-qPCR and the relative expression of NRP1-FS and NRP1-Δ7 were calculated as
described in Material and Methods. Induced expression of recombinant NRP1 by dox increases the relative proportion of
NRP1-FS (A) or NRP1-Δ7 (B) in the corresponding clones. Due to the small difference in size (7 amino acids), NRP1-FS and
NRP1-Δ7 cannot be discriminated by western blotting. Increases in total NRP1 protein expression is however observed in
presence of dox. 28S rRNA and ERK1/2 were used as control for, respectively, RT-PCR and western blotting analysis.
doi:10.1371/journal.pone.0165153.g004
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NRP1-Δ7 Antagonizes Tumor Growth and Vascularization In Vivo
For evaluating the role of NRP1-Δ7 in in vivo tumorigenesis, PC3/TR/NRP1-Δ7 cells were
injected in the flank of nude mice. Control mice had access to regular water while the water of
NRP1-Δ7 mice was supplemented with doxycycline. After 7 weeks, mice were sacrificed and
the tumors weighed (Fig 9A–9C). Expression of NRP1 in tumors was determined by RT-PCR.
In control tumors, NRP1-Δ7 represents roughly 20% of the total amount of NRP1, while this
proportion rises to 50% upon doxycycline treatment, as also observed in in vitro experiments.
A significant inhibition of growth was observed in tumors formed by NRP1-Δ7 overexpressing
cells as compared to the tumors formed by the same pool of cells in absence of doxycycline.
Tumors vascularizationwas evaluated by labeling with anti-CD31 antibodies (Fig 9D–9F). A
significantly decreased number of intratumoral blood vessels per unit surface as well as a
Fig 5. NRP1-Δ7 inhibits migration of PC3 cells. A wound scratch assay was performed according to the procedure described in
Materials and Methods using the doxycycline-inducible PC3 cells overexpressing NRP1-FS (PC3/TR/NRP1-FS) or NRP1-Δ7 (PC3/TR/
NRP1-Δ7) with (dox+) or without (dox-) doxycycline. Pictures were taken at the start of the experiment (0h) and 24 hours later (24h).
Pictures of representative experiments are shown and the means ± SD are illustrated in the graphs (n = 12, for each cell line; *: p<0.05
and ***: p<0.001, Mann-Whitney U test)—Scale bar = 200 μm.
doi:10.1371/journal.pone.0165153.g005
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Fig 6. NRP1-Δ7 reduces cancer cell proliferation in vitro. Doxycycline-inducible PC3 and MDA-MB-231
cells able to express recombinant NRP1-FS (FS) or NRP1-Δ7 (Δ7) were seeded in 24-well plates in
presence (dotted lines) or absence (continuous lines) of 200 ng/ml doxycycline and collected at the indicated
times. The DNA content of each well was measured as described in Materials and Methods (n = 4, *: p<0.05,
**: p<0.01 and ***: p< 0.001 as determined by Anova).
doi:10.1371/journal.pone.0165153.g006
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reduction of the surface covered by blood vessels was observed in tumors overexpressing
NRP1-Δ7.
Fig 7. Overexpression of NRP1-Δ7 inhibits anchorage-independent growth of PC3 and MDA-MB-231
cells. Doxycycline-inducible PC3 and MDA-MB-231 clones able to express recombinant NRP1-FS (FS) or
NRP1-Δ7 (Δ7) were plated in soft agar as described in Materials and Methods. Cells were supplemented
(dox+) or not (dox-) with weekly renewed doxycycline (1 μg/ml). After 3 weeks of culture, colonies were
counted in the whole dishes. Results are represented as the number of colonies expressed as mean ± SD.
Representative results of two independent experiments performed in quadruplicates are shown (*: p<0.05,
as determined by Mann-Whitney U test).
doi:10.1371/journal.pone.0165153.g007
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Discussion
The neuropilin-1 pre-mRNA is alternatively spliced in several mature mRNA encoding pro-
teins with various, sometimes opposite, properties. The full size NRP1 is anchored in the cell
Fig 8. NRP1-FS and NRP1-Δ7 are differentially relocalized after VEGF-A165 stimulation. PC3 clones induced (dox at 200 ng/ml) to
express FLAG-tagged NRP1-FS or NRP1-Δ7 were serum-starved for 24h before exposure or not to VEGF-A165 for 10 minutes.
Immunofluorescence analyses were performed using a FLAG antibody and imaging parameters were set to visualize (A) the total amount of
tagged-NRP1 or (B) only NRP1 associated with intracellular vesicles in the same cells as in (A). Quantification of the intracellular vesicular
NRP1 was performed as described in Materials and Methods. Results are expressed as the mean ± SD (n = 69, FS, 0 VEGF; n = 110, FS
+VEGF; n = 77 Δ7, 0 VEGF and n = 72, Δ7, +VEGF; ***: p<0.001, Mann-Whitney U test)—Scale bar = 10 μm.
doi:10.1371/journal.pone.0165153.g008
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membrane, functions as a co-receptor for multiple ligands such as VEGF-A165, TGF-β and
semaphorinA, and forms complexes with their signaling receptors. NRP1 is also involved in
endocytosis and initiates intracellular trafficking of a number of membrane receptors. The sol-
uble isoforms of NRP1 (NRP1-s11 and -s12) act in several settings as antagonists of neuropi-
lin-1 signaling,mainly by competitive binding to the ligands [16]. Here we report the
characterization of a novel variant (NRP1-Δ7) which differs from the full size form by the
absence of a 7 amino acids sequence (GDDFQLT) located 2 amino acids downstream of Ser612,
the main O-glycosylation site on NRP1.We have shown that NRP1-Δ7 is significantly and dif-
ferently expressed in various cell types of human and mouse origin, varying between 10 and
30% of total NRP1, which suggests a specific physiological function. The ability of cells to add
glycosaminoglycan chains strongly depends upon the amino acids sequence around the glyco-
sylation site [26]. For instance, Zhang and colleagues showed that a serine-glycine peptide
flanked by acidic residues favored the addition of heparan sulfate [18]. In NRP1-FS, the
sequence around Ser612 (S612GTGDDF) contains two “D” acidic residues, while the
“GDDFQLT” deletion in NRP1-Δ7 results in a more hydrophobic consensus sequence
(S612GTGGTT)which is likely responsible for the defective O-glycosylation of NRP1-Δ7
reported here. Alterations of NRP1 glycosylation, induced enzymatically or by mutations of
Ser612, profoundly alter cancer cells phenotype [10, 13]. The role of the naturally occurring
NRP1-Δ7 was therefore evaluated in functional assays relevant to cancer biology. For this pur-
pose, prostate (PC3) and breast (MDA-MB-231) adenocarcinoma cells were used as models
since they express a significant level of endogenous neuropilin-1 and are known to respond to
activation of neuropilin-1-dependent pathways [22–24]. They were modified to conditionally
express either recombinant NRP1-FS or NRP1-Δ7 upon doxycycline treatment. As a conse-
quence, the relative proportion of NRP1-Δ7, which is around 20% in control cells, is decreased
to about 10% in doxycycline-inducedNRP1-FS while it reaches almost 50% in doxycycline-
treated NRP1-Δ7 clones. It has to be pointed out that, in our inducible model, the total amount
of expressed NRP1 is never increased by more than about two fold, which is important to pre-
vent non-relevant effects that could be induced by an excessive overexpression of recombinant
proteins.
NRP1-FS is known to regulate cell functions involved in cancer progression such as prolifer-
ation, migration or anchorage-independent growth [9, 13, 27]. However, all the previous stud-
ies related to endogenous NRP1 did not consider separately NRP1-FS and NRP1-Δ7. The
observed effects could thus reflect the net results of a balance between two NRP1 isoforms with
opposite functions. By specifically evaluating the functions of NRP1-Δ7, we demonstrated here
that its overexpression to the same level as endogenous NRP1-FS was sufficient to significantly
decrease the proliferation rate, the migration and the anchorage-independent growth of pros-
tatic and breast cancer cells, pointing to an anti-tumorigenic potential of NRP1-Δ7. It is well
known that NRP1 forms clusters with various growth factor receptors like VEGFR and c-Met,
or plexins, and serves as a guide during their intracellular recycling [28]. It was also shown that
Fig 9. NRP1-Δ7 inhibits tumor growth and vascularization in vivo. (A) 2 x 106 PC3/TR/ NRP1-Δ7 cells were
injected in each flank of nude mice (n = 8 mice). The animals were separated in two groups. The expression of the
transgene was induced in one group by adding doxycycline (2 mg/ml) in drinking water. After 7 weeks, mice were
sacrificed. The tumors were macroscopically observed (A), measured and weighed (B) (n = 15 tumors in control
condition and n = 14 tumors in doxycycline-induced mice) and processed for total RNA extraction and measurement
of both variants by RT-PCR (C). The relative proportion of NRP1-Δ7 increases from 20 to 50% in presence of dox.
(D) Immunological analysis of tumor vascularization by CD31 immunostaining. (E) The number of blood vessels per
unit surface was determined and (F) the surface covered by blood vessels was calculated and expressed in %.
Results are expressed as the mean ± SD of n = 13 tumors in control condition and n = 10 tumors in doxycycline-
induced mice (*: p<0.05, Mann-Whitney U test)—Scale bar = 100 μm.
doi:10.1371/journal.pone.0165153.g009
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VEGF-A and TGF-β can markedly affect the phenotype and aggressiveness of PC3 cells [24].
By analyzing the subcellular dynamics of NRP1-FS and NRP1-Δ7, we showed that NRP1-Δ7 is
less internalized than NRP1-FS upon VEGF-A binding. These results suggest that the associa-
tion of NRP1-Δ7 with transmembrane growth factor receptors could affect their intracellular
recycling which might inhibit their downstream signaling pathways. Alternatively, NRP1-Δ7
could exert its anti-tumorigenic activity by competing with NRP1-FS for binding to ligands as
reported for the soluble forms of NRP1. NRP1-Δ7 could also mediate its anti-tumorigenic
effects via cell adhesion receptors like integrins. NRP1 can indeed synergize with these extracel-
lular matrix receptors to promote cancer cell proliferation, migration or colony formation in
soft agar in vitro [9, 13, 27] and to stimulate in vivo tumor growth and vascularization [29].
The potential anti-tumorigenic properties of NRP1-Δ7 were therefore evaluated in vivo by
using inducible PC3/TR/NRP1-Δ7 in a xenograft model. As observed in vitro, the addition of
doxycycline in drinkingwater allowed continuous expression of NRP1-Δ7 in the xenografts.
Using this model, we clearly demonstrated that increased expression of NRP1-Δ7 inhibits
tumor growth and intratumoral angiogenesis.
This report is the first study characterizing the specific functions of NRP1-Δ7, a glycosami-
noglycan-defective neuropilin-1 splice variant that displays anti-tumorigenic properties in
vitro and in vivo. Although the precise mechanisms of regulation depending on NRP1-Δ7 were
not identified, our observations emphasize the critical importance of considering specifically
the different NRP1 variants, especiallyNRP1-Δ7, instead of analyzing the whole NRP1
expression.
Supporting Information
S1 Fig. Neuropilin-1-ΔE16 splice variant constitutes a minor fraction of the total amount
of NRP1. Specific primers were designed to co-amplify the NRP1-FS and the NRP1-ΔE16 vari-
ant in PC3 and MDA-MB-231. NRP1-ΔE16 variant corresponds to 1% and 3% of NRP1-FS in,
respectively, MDA-MB-231 and PC3 cells.
(TIF)
S2 Fig. RT-qPCR quantification of NRP1-FS and NRP1-Δ7 expression. RT-qPCR measure-
ments were performed on total RNA extracted from cells and tissues from human (A) and
mouse (B) origin as detailed in Materials and Methods. The ΔCt and the ratio Δ7/FS were cal-
culated as described in Materials and Methods. (C) At the end of the run, the amplification
products of NRP1-FS and NRP1-Δ7 were separated by gel electrophoresis and displayed the
expected size.
(TIF)
S3 Fig. RT-qPCR quantification of NRP1-FS and NRP1-Δ7 expression in the doxycycline-
inducible clones. PC3 or MDA-MB-231 (MDA) clones with inducible expression of recombi-
nant full size NRP1 (FS) or recombinant NRP1-Δ7 (Δ7) were cultured for 24h in absence (-) or
presence (+) of doxycycline (dox) at 200 ng/ml. For each clone, cells were processed for total
RNA extraction to perform RT-qPCR analyses. The ΔCt and the ratio Δ7/FS were calculated as
described in Materials and Methods.
(TIF)
S4 Fig. Doxycycline by itself has no effect on the studied biological processes.Migration,
proliferation and growth in soft agar assays were performed in absence and presence of doxy-
cycline on cells transfected with an empty vector to assess the absence of influence of doxycy-
cline by itself on these processes.
(TIF)
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S5 Fig. Additional clones tested in scratch wound healing assay. Additional clones of PC3
and MDA-MB-231 were used for the evaluation of the NRP1 isoform-related effects on the cell
migration.
(TIF)
S6 Fig. NRP1-FS or NRP1–Δ7 overexpression does not alter cell apoptosis.Apoptosis was
evaluated by flow cytometry analysis of doxycycline-inducible clones of PC3 overexpressing
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